Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

September 28, 2007
Past Lexiva Treatment May Reduce Benefit From Prezista
A recent study reported by AIDSmap has found that some people who have developed drug resistance to the protease inhibitor (PI) Lexiva (fosamprenavir) may have a reduced benefit from another PI, Prezista (darunavir).
September 27, 2007
Ban on European Viracept Sales Lifted
The European Medicines Agency (EMEA) has announced that it is lifting its recent ban on the sale of Viracept (nelfinavir) in Europe, according to the Associated Press.
KP-1461: A New Approach to HIV Treatment Now in Studies
A completely new type of antiretroviral drug—KP-1461, manufactured by Koronis Pharmaceuticals—has entered the human testing phase.
September 26, 2007
Transcript: Wisdom for Women: An Expert's Take on HIV and Gender Differences
Genetic Tests Could Help Reduce Sustiva Side Effects
Japanese researchers have found that some people can safely reduce their dose of Sustiva (efavirenz) and possibly reduce the chance of side effects.
September 25, 2007
High Rate of Kidney Problems in HIV
A high rate of kidney problems in HIV-positive people has been documented in a New York study.
Dry Skin More Common in Positive People
Dry skin is more common in people with HIV than in people who are HIV negative, according to a new study published in the journal AIDS.
September 24, 2007
Etravirine for NNRTI-Resistant HIV: Pooled DUET Study Results
A combined analysis of two Phase III clinical trials of etravirine suggests that the drug is promising for treatment-experienced patients, when combined with an optimized background regimen (OBR).
Activist Seek Fair Price for Isentress
A coalition of AIDS activists is calling on Merck & Co. Inc. to set a fair and reasonable price for their integrase inhibitor Isentress (raltegravir).
Maraviroc Gets EU Approval
Pfizer Inc announced today that the European Commission has approved the antiretroviral drug maraviroc for treatment-experienced patients in the European Union (EU).
September 21, 2007
Single-Dose PRO 140 Has Lasting Effects
Researchers once again reported promising results from an early study of PRO 140, an experimental HIV entry inhibitor.
48-Week Selzentry Data Show Promise for Drug-Resistant HIV
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
September 20, 2007
Wisdom for Women: An Expert's Take on HIV and Gender Differences
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research.
Selzentry Treatment Failure: The Impact of Tropism Changes
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s.
Two-Year Vicriviroc Benefit in Treatment-Experienced Patients
Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in treatment-experienced patients who combine the drug with an optimized background regimen (OBR). 
FDA Grants Priority Review for New NNRTI, Etravirine
The Food and Drug Administration (FDA) has granted priority review status for etravirine (also known as TMC125), according to an announcement by Tibotec Pharmaceuticals Ltd.
HIV Prevalence Declines in Pregnant Women in Zimbabwe
Of a new study presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago (ICAAC) this week, AIDSmap reports that the percentage of pregnant women who tested positive at a Zimbabwe hospital dropped by 41 percent between 1999 and 2007.
September 19, 2007
Coming Down the Pike: Expanding HIV Treatment Options
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every other week.
IL-2 May Delay Need for Antiretroviral Treatment
An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high and postpone their need to begin antiretroviral therapy.
Elvitegravir Study Highlights Value of Strong Background Regimen
Like all other promising experimental drugs, Gilead’s elvitegravir needs to be combined with other active drugs to which HIV is sensitive. 
New Data Explores Current Treatment Options
Peter Staley asks Dr. Joe Eron about the good news on a challenging drug -- newly-approved Selzentry -- and the very potent new protease inhibitor, Prezista.
September 18, 2007
Interview with a Hep C Activist & Survivor
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, about the latest in HCV treatment and prevention.
Heart Disease Risk Remains in Absence of HIV Treatment
There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is.
Prezista Shows Well in Patients New to Treatment
Prezista may be approved only for treatment-experienced patients, but new data suggest that it may have a lot to offer treatment newbies as well. 
Isentress Offers Long-Term Benefits for Drug-Resistant Patients
New follow-up data from a Phase II clinical trial evaluating Merck's integrase inhibitor Isentress suggests that the drug may offer long-term benefits to HIV-positive people with extensive treatment experience and drug resistance.
Secrets of a Long-Term Survivor
Peter Staley talks with Matt Sharp about his activism, his new regimen, and his facial lipo fix.
September 17, 2007
High Risk of Peripheral Artery Disease in HIV
Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.
Lexiva and Kaletra Comparable in Long-Term Study
New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness.
September 14, 2007
Pregnancy Protective Against HIV Disease Progression
New data published in the October 1 issue of the Journal of Infectious Diseases reveal that pregnancy may actually have protective health effects for HIV-positive women.
Skin Test Predicts Control of HPV
A new study shows that a simple skin-prick test may be useful in helping HIV-positive women determine if their immune systems are strong enough to control cancer-causing human papilloma virus (HPV) infection.
September 13, 2007
More Reports on Kidney Stones With Reyataz
A French study, published in the September 12 issue of Clinical Infectious Diseases, mirrors another report from the United States suggesting that kidney stones may be a side effect of the protease inhibitor Reyataz.
September 12, 2007
Lasting CD4 Increases With IL-2
Results from a new study justify scientists’ continuing interest in interleukin-2 (IL-2) therapy for HIV.
September 11, 2007
Pfizer Warns of Cancerous Impurity in Viracept
Pfizer is warning of a potentially cancerous impurity in Viracept and is now recommending that the protease inhibitor not be used by pregnant women and that children not start it.
HIV Damages Brain Despite Treatment
HIV treatment may not fully protect the brain or eliminate the risk of impaired brain functioning, according to a new study published in the September issue of AIDS and reported today by AIDSmap.
September 10, 2007
High-Fat Diets Affect Disease Progression
Scientists have added another strike against high-fat diets. A recent animal study in the Journal of Infectious Diseases suggests that a diet high in saturated fat and cholesterol may accelerate HIV disease progression.
September 07, 2007
Study Suggests Treating Hep C Before HIV
More evidence has arrived suggesting that treating hepatitis C (HCV) before HIV is a good idea, when possible.
September 06, 2007
Isentress Recommended for FDA Approval
As widely reported yesterday, an advisory committee to the FDA has unanimously voted to recommend approval for Isentress—the first of a new class of antiviral drug known as an integrase inhibitor—for use in people who’ve developed resistance to other drugs.
September 05, 2007
Promising New Nuke, Apricitabine
A new drug in development, apricitabine (ATC), may have moved another step closer toward inclusion in the arsenal of drugs approved to fight HIV. 
September 04, 2007
Needle-Free Device Improves Life for Fuzeon Users
People who use Fuzeon, an injectable antiviral drug known as a fusion inhibitor, should toss their syringes according to a study published in the October issue of the journal, HIV Medicine
Metformin Shows Little Lipodystrophy Benefit in Small Study
New research suggests that lipodystrophy sufferers should approach metformin with caution. 
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.